Oppenheimer Initiates Coverage On Retension Pharmaceuticals with Outperform Rating, Announces Price Target of $50
Benzinga Newsdesk 15 hours ago
Analyst RatingsNewsInitiationPrice Target
Oppenheimer analyst Jay Olson initiates coverage on Retension Pharmaceuticals (NASDAQ:RTSN) with a Outperform rating and announces Price Target of $50.
Oppenheimer analyst Jay Olson initiates coverage on Retension Pharmaceuticals (NASDAQ:RTSN) with a Outperform rating and announces Price Target of $50.